CARDIOMETABOLIC CONDITIONSPIVOTNCT05654142
The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older
A study testing Base intervention and Augmented Intervention in people with CARDIOMETABOLIC CONDITIONS and Obesity, run by University of Illinois at Chicago at 3 sites in United States.
Trial summary
This is a multisite clinical trial of healthy lifestyle programs for middle-to-older-aged adults (50 -74 years) to improve their weight and, therefore, reduce risk for chronic disease. Read more about this study
- Who is it for?
- Ages 50 to 74 years
- Conditions the study is for
- CARDIOMETABOLIC CONDITIONS, Obesity, Pre-diabetes
- What is being tested?
- Base intervention and Augmented Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,029 participants
- Where
- 3 sitesUnited States
- Study dates
- 17 Apr 2023to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 74 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 50 - 74 years (inclusive)
- Confirmed body mass index (BMI) ≥27.0 based on:
- Weight measured by participant at home using the study-provided wireless weight scale
- Height documented in the EHR during at least 2 separate ambulatory care encounters within the past 2 years
- Diagnosis of 1 or more cardiometabolic condition (prediabetes, metabolic syndrome, type 2 diabetes, hypertension, dyslipidemia) in the EHR
- Willing and able to accept randomization, and provide written informed consent and HIPAA authorization
- Willing and able to participate in all aspects of the data collection and intervention protocols, including remote monitoring with a study-provided wireless weight scale and activity tracker and the use of a study tablet for access of MyChart, REDCap, and Fitbit apps
Who cannot join
- Unable to speak, read, understand English sufficiently for informed consent
- No reliable Wi-Fi Internet access at home
- Self-report of current active weight loss treatment, including research-based commercial weight loss programs (e.g., Weight Watchers, Jenny Craig, HMR, Omada, TOPS), other weight loss or related behavioral health or wellness programs led by trained personnel (professional or lay) at the recruiting clinic or in the local community, and prescription weight loss medications
- Screen positive for active eating disorder (bulimia nervosa or binge eating disorder) using PHQ- eating disorder module
- Planned or prior bariatric surgery within the last 2 years (Note: patients who are more than 2 years post bariatric surgery can participate if otherwise eligible)
- Unable to pass the Revised Physical Activity Readiness Questionnaire (PAR-Q) or obtain physician medical clearance to participate
Show all 13Show fewer
- Presence of any significant safety concerns or contraindications related to serious physical or mental health issues based on the EHR or self-report (e.g., type 1 diabetes or insulin dependence, myocardial infarction, stroke, cancer diagnosis (other than non-melanoma skin cancer) within the past 12 months and/or actively receiving cancer treatment, end-stage organ failure, bipolar disorder, psychosis, life expectancy <12 months)
- Cognitive impairment based on the Callahan 6-item screener
- Active alcohol or substance use disorder (including prescription drugs) based on the CAGE Questionnaire Adapted to Include Drugs (CAGE-AID)
- Discontinued health care at the recruiting site, or plan to discontinue in the next 12 months
- Participation in other behavioral, medical or surgical treatment studies by self-report that conflict with the primary weight loss outcome of this study.
- Family/household member of an already enrolled participant or of a study team member
- Investigator discretion for clinical safety or protocol adherence reasons
Trial locations and contacts
3 sites in 1 country.
United States3 sites
Department of Medicine, Vitoux Program on Aging and Prevention
Chicago, Illinois, 60608
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, 15213
Washington University School of Medicine in St Louis
St Louis, Missouri, 63110
About this study
This is a multisite clinical trial of healthy lifestyle programs for middle-to-older-aged adults (50 -74 years) to improve their weight and, therefore, reduce risk for chronic disease. This study will investigate whether a proven, self-directed video-based lifestyle program can be significantly enhanced with the assistance of a coach via videoconference or phone to help people as they adopt healthy eating and exercise behaviors. Additionally, the study will examine what factors might explain why some people achieve better outcomes than others. Understanding this can help to tailor the program to an individual for personalized care in the future.
Importantly, this study aims to demonstrate how readily a digital lifestyle program, with or without remote coaching, can be seamlessly delivered to patients at home via the patient portal of their electronic health record. This practical use of existing telehealth tools could be a feasible and effective means to offer behavioral treatments during routine medical care.
Read the detailed description
This multisite clinical trial uses a 2-stage sequential randomization design to test the adaptive and nonadaptive augmentation of a validated Group Lifestyle Balance (GLB) video program (base intervention) using problem solving treatment (PST), a proven behavior therapy. The GLB video program will be delivered via the patient portal of the electronic health record system. Trained coaches will deliver PST remotely via videoconference or phone.
English-speaking adults (N=1029), 50-74 years of age with a body mass index ≥27 and ≥1 cardiometabolic conditions, will be randomized at baseline to base intervention or waitlist control. Participants initially randomized to the waitlist control will be re-randomized after a 12-week control period to receive the base (Group A) or the augmented intervention (Group B), without tailoring based on early weight loss. Among participants initially randomized to the base intervention, responders defined by ≥3% weight loss at 6 weeks will continue the base intervention (Group C); nonresponders who are participants with <3% weight loss or missing weight data by 6 weeks will be re-randomized to continue the base intervention alone (Group D) or augmented with PST coaching via videoconference (Group E).
The investigators hypothesize: (1) the augmented intervention will be more effective than the base intervention both among early nonresponders to the base intervention (adaptive) and among participants in the waitlist control condition (nonadaptive) at 52 weeks; (2) the adaptive augmented intervention will be more efficacious than the base intervention and more efficacious than the waitlist control condition at 12 weeks. Aim 2 is to identify predictors of clinically significant (5%) weight loss for individual patients, using sociodemographic, clinical and behavioral engagement characteristics.
- Conditions
- CARDIOMETABOLIC CONDITIONS, Obesity, Pre-diabetes, Metabolic Syndrome, Type2diabetes, Hypertension
- Being tested
- Base intervention, Augmented Intervention
- Medical subject headings
- Obesity, Glucose Intolerance, Metabolic Syndrome, Hypertension, Dyslipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Base interventionBehavioural
12 Group Lifestyle Balance videos and digital motivational messages
Augmented InterventionBehavioural
12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone
| Study group | Role | What they receive |
|---|---|---|
| Group A: Waitlist-Base Intervention | Active comparator | Participants in Group A will be in the waitlist control condition initially and transition to receive the base intervention at Week 12, which includes 12 GLB video sessions from Week 13-24 and digital messages from Week 25-52. Receives: Behavioral: Base intervention |
| Group B: Waitlist-Augmented Intervention | Active comparator | Participants in Group B will be in the waitlist control condition initially and transition to receive the augmented intervention at Week 12, which includes 12 GLB video sessions plus one-on-one PST from Week 13-24 and digital messages plus group-based PST from Week 25-52. Trained coaches will deliver the PST via videoconference (preferred) or phone. Receives: Behavioral: Augmented Intervention |
| Group C: Base Intervention (Responders) | Experimental | Participants in Group C will be the individuals initially randomized to receive the base intervention who achieve 3% weight loss or more by Week 6 after completing the first 6 GLB videos. They will continue the base intervention without re-randomization and complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. Receives: Behavioral: Base intervention |
| Group D: Base Intervention (Non-responders) | Experimental | Participants in Group D will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to continue the base intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. Receives: Behavioral: Base intervention |
| Group E: Augmented Intervention (Non-responders) | Experimental | Participants in Group E will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to receive the augmented intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. They will also work with a trained coach via videoconference (preferred) or phone to receive one-on-one PST from Week 7-24 and group-based PST from Week 25-52. Receives: Behavioral: Augmented Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess change in weight from baseline to 52 weeks
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0) and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
Measured: Baseline, 52 weeks
Secondary outcomes (22)
Assess change in weight from baseline to 12 weeks
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0) and 12 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
Measured: Baseline, 12 weeks,
Assess trajectories of weight change from baseline to 6, 12, 24, and 52 weeks
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0), 6, 12, 24, and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks
Assess changes in number of steps using Fitbit activity tracker at 6, 12, 24 and 52 weeks
All participants will receive a study-provided Fitbit Inspire 3 activity tracker with heart rate and sleep monitor, assistance with account and device setup. At 0, 6, 12, 24 and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to wear their activity tracker for at least 10 hours on 3 or more days during the week. The investigators will obtain participants' self-monitored number of steps using a developed program for automated daily synchronization via the Fitbit open API.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in sleep metrics using Fitbit activity tracker at 6, 12, 24 and 52 weeks
All participants will receive a study-provided Fitbit Inspire 3 activity tracker with heart rate and sleep monitor, assistance with account and device setup. At 0, 6, 12, 24 and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to wear their activity tracker for at least 10 hours on 3 or more days during the week. The investigators will obtain participants' self-monitored sleep metrics using a developed program for automated daily synchronization via the Fitbit open API.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in physical activity using the International Physical Activity Questionnaire at 6, 12, 24 and 52 weeks
All participants will self-administer the International Physical Activity Questionnaire (IPAQ), a 7-item questionnaire that captures a participant's physical activity over the last 7 days.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in fruit/veggie/fat/fiber intake at 6, 12, 24 and 52 weeks
Dietary intake will be measured using 17-item fruit, vegetable, fat, and fiber screener by self-report. Correlations between screener estimates and estimated true intake were 0.5-0.8.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in efficacy in weight control at 6, 12, 24 and 52 weeks
Participants will complete validated self-administered scale of self-efficacy for weight control using the Weight Efficacy Lifestyle Questionnaire. Sum of scores of 8 items, with a range between 0 and 80. Higher scores indicate higher self-efficacy to control eating behaviors.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in efficacy in diet change at 6, 12, 24 and 52 weeks
Participants will complete validated self-administered scale of self-efficacy for dietary change using the Eating Habits Confidence Survey. The total score is mean item scores, with a range between 1 and 5. Higher scores indicate higher diet self-efficacy (i.e., higher ability to avoid eating certain unhealthy foods).
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in efficacy in physical activity at 6, 12, 24 and 52 weeks
Participants will complete validated self-administered scale of self-efficacy for physical activity using the Exercise Confidence Survey. The total score is mean item scores, with a range between 1 and 5. Higher scores indicate higher exercise self-efficacy (i.e., greater confidence in performing certain behaviors consistently for at least 6 months).
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in social support/autonomous support per Health Care Climate Questionnaire at 6, 12, 24 and 52 weeks
Participants will complete the Health Care Climate Questionnaire (HCCQ), which assessed their perceptions of the autonomy supportiveness of their care team. HCCQ contains 15 items, rated on a 5-point scale ranging from "not true at all" to "very true." After reversing the score of a negative item, an average score is calculated with higher score indicating a higher level of perceived autonomy support.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in problem solving ability at 6, 12, 24 and 52 weeks
Participants' problem solving abilities will be assessed using the reliable and valid SPSI-R:S that contains 25 items in the following 5 subscales: positive problem orientation (PPO), negative problem orientation (NPO), rational problem solving (RPS), impulsive/careless style (ICS), and avoidance style (AS). Each item is rated on a 5-point scale ranging from "not at all true of me" (0) to "extremely true of me" (4). SPSI-R:S is a short version of the long SPSI-R:L form which has Cronbach's alpha coefficient of 0.95 for the total score and of 0.67-0.92 for subscales.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in patient activation at 6, 12, 24 and 52 weeks
The 13-item PAM measures patient's self-reported knowledge, skill, and confidence for self-managing his or her health condition. It demonstrated acceptable internal consistency (Conbrach's alpha = 0.81). The 13-item PAM score accounts for 92% of the variation in the activity measured by the original 22-item PAM. The score is also significantly correlated with general preventive behaviors and disease-specific self-management behaviors.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in perceived stress at 6, 12, 24 and 52 weeks
Perceived Stress Scale (PSS) measures the perception of stress (i.e., the degree to which situations in one's life are appraised as stressful). PSS contains 14 items, rated on a 5-point scale ranging from "never" to "very often." After reversing the scores on 7 positive items, a sum of score is calculated with higher score indicating higher perceived stress. Cronbach's alpha ranged from 0.84 to 0.86.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in sleep disturbance score at 6, 12, 24 and 52 weeks
Sleep disturbance is assessed on the 8-item PROMIS sleep disturbance scale short form which measures symptoms of insomnia. Each item is scaled from 1 (not at all) to 5 (very much). Sleep disturbance score=(Raw sum ×number of items on the short form) / number of items answered. The higher the score the greater sleep disturbance.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in sleep impairment score at 6, 12, 24 and 52 weeks
Sleep impairment is assessed on the 8-item PROMIS sleep-related impairment scale short form which measures symptoms of daytime sleepiness. Each item is scaled from 1 (not at all) to 5 (very much). Sleep impairment score=(Raw sum ×number of items on the short form) / number of items answered. The higher the score the greater sleep impairment.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in cognitive functioning at 6, 12, 24 and 52 weeks
Cognitive functioning will be assessed on the PROMIS version 1.0 short-form subscales of Cognitive Abilities and Cognitive Concerns. Each subscale contains 8 items. The Cognitive Abilities items target positive self-assessments of cognitive functioning such as "My memory has been as good as usual" and "I have been able to concentrate." The Cognitive Concerns items are worded negatively and express concerns in the same areas, for examples, "My thinking has been slow" and "I have had trouble shifting back and forth between different activities that require thinking." Items on both subscales use a 5-point rating from "not at all" to "very much." Items are summed to create a total score for each subscale.
Measured: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in cardiovascular risk at 52 weeks
The non-laboratory Framingham risk prediction model estimates individuals' 10-year risk of developing any major atherosclerotic cardiovascular disease (CVD) event. The component risk factors are age, BMI, systolic blood pressure, smoking status, presence of diabetes, and medication for high blood pressure. Participants will be asked to confirm their age and report their smoking history at baseline and current smoking status at baseline and 52 weeks. The BMI will be calculated based on participants' self-measured weight data as described above and height measurements abstracted from their EHR. Blood pressure, diagnosis of diabetes, and prescriptions for high blood pressures will also be abstracted from the EHR.
Measured: Baseline, 52 weeks
Assess changes in number/severity of comorbidity at 52 weeks
The Cumulative Illness Rating Scale (CIRS) is a composite index of the number and severity of medical problems by organ system. It has been validated in diverse populations and settings, including primary care patients, with published guidelines and electronic tools for application and scoring using electronic health record (EHR) data.
Measured: Baseline, 52 weeks
GLB videos viewed
GLB videos viewed will be automatically tracked.
Measured: Throughout the intervention, up to 1 year
PST coaching sessions completed
PST coaching sessions completed will be recorded by coach in REDCap.
Measured: Throughout the intervention, up to 1 year
Self-monitoring of weight
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). Participants will be encouraged to weigh themselves at least 3 days a week throughout the study. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible) at consistent time. They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
Measured: Through study completion, an average of 1 year
Self-monitoring of activity & sleep
All participants will receive a study-provided Fitbit Inspire 3 activity tracker with heart rate and sleep monitor, assistance with account and device setup. Participants will be encouraged to wear their activity tracker for at least 10 hours on 3 or more days a week throughout the study. The investigators will obtain participants' self-monitored number of steps and sleep metrics using a developed program for automated daily synchronization via the Fitbit open API.
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2022
- Study start17 Apr 2023
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CARDIOMETABOLIC CONDITIONSStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 1,029 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Illinois at Chicago
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jun Ma, University of Illinois at Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05654142
- Sponsor's protocol ID
- 2022-1230
- Acronym
- PIVOT
- Status last verified
- Aug 2026
- First submitted
- 8 Dec 2022
- Last updated
- 31 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The PIVOT Trial: Project on EHR-Integrated Lifestyle Interventions for Adults Aged Fifty and Older
- ClinicalTrials.gov ID
- NCT05654142
- Acronym / sponsor ID
- PIVOT / 2022-1230
- Conditions
- CARDIOMETABOLIC CONDITIONS, Obesity, Pre-diabetes, Metabolic Syndrome, Type2diabetes, Hypertension
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,029 participants (actual)
- Lead sponsor
- University of Illinois at ChicagoUniversity, hospital or other
- Collaborators
- Washington University School of Medicine, University of Pittsburgh
- Study start
- 17 Apr 2023 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 16 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a multisite clinical trial of healthy lifestyle programs for middle-to-older-aged adults (50 -74 years) to improve their weight and, therefore, reduce risk for chronic disease. This study will investigate whether a proven, self-directed video-based lifestyle program can be significantly enhanced with the assistance of a coach via videoconference or phone to help people as they adopt healthy eating and exercise behaviors. Additionally, the study will examine what factors might explain why some people achieve better outcomes than others. Understanding this can help to tailor the program to an individual for personalized care in the future.
Importantly, this study aims to demonstrate how readily a digital lifestyle program, with or without remote coaching, can be seamlessly delivered to patients at home via the patient portal of their electronic health record. This practical use of existing telehealth tools could be a feasible and effective means to offer behavioral treatments during routine medical care.
Detailed description
This multisite clinical trial uses a 2-stage sequential randomization design to test the adaptive and nonadaptive augmentation of a validated Group Lifestyle Balance (GLB) video program (base intervention) using problem solving treatment (PST), a proven behavior therapy. The GLB video program will be delivered via the patient portal of the electronic health record system. Trained coaches will deliver PST remotely via videoconference or phone.
English-speaking adults (N=1029), 50-74 years of age with a body mass index ≥27 and ≥1 cardiometabolic conditions, will be randomized at baseline to base intervention or waitlist control. Participants initially randomized to the waitlist control will be re-randomized after a 12-week control period to receive the base (Group A) or the augmented intervention (Group B), without tailoring based on early weight loss. Among participants initially randomized to the base intervention, responders defined by ≥3% weight loss at 6 weeks will continue the base intervention (Group C); nonresponders who are participants with <3% weight loss or missing weight data by 6 weeks will be re-randomized to continue the base intervention alone (Group D) or augmented with PST coaching via videoconference (Group E).
The investigators hypothesize: (1) the augmented intervention will be more effective than the base intervention both among early nonresponders to the base intervention (adaptive) and among participants in the waitlist control condition (nonadaptive) at 52 weeks; (2) the adaptive augmented intervention will be more efficacious than the base intervention and more efficacious than the waitlist control condition at 12 weeks. Aim 2 is to identify predictors of clinically significant (5%) weight loss for individual patients, using sociodemographic, clinical and behavioral engagement characteristics.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Sequential
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Group A: Waitlist-Base Intervention | Active comparator | Behavioral: Base interventionParticipants in Group A will be in the waitlist control condition initially and transition to receive the base intervention at Week 12, which includes 12 GLB video sessions from Week 13-24 and digital messages from Week 25-52. |
| Group B: Waitlist-Augmented Intervention | Active comparator | Behavioral: Augmented InterventionParticipants in Group B will be in the waitlist control condition initially and transition to receive the augmented intervention at Week 12, which includes 12 GLB video sessions plus one-on-one PST from Week 13-24 and digital messages plus group-based PST from Week 25-52. Trained coaches will deliver the PST via videoconference (preferred) or phone. |
| Group C: Base Intervention (Responders) | Experimental | Behavioral: Base interventionParticipants in Group C will be the individuals initially randomized to receive the base intervention who achieve 3% weight loss or more by Week 6 after completing the first 6 GLB videos. They will continue the base intervention without re-randomization and complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. |
| Group D: Base Intervention (Non-responders) | Experimental | Behavioral: Base interventionParticipants in Group D will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to continue the base intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. |
| Group E: Augmented Intervention (Non-responders) | Experimental | Behavioral: Augmented InterventionParticipants in Group E will be the individuals initially randomized to receive the base intervention who do not achieve 3% weight loss by Week 6 after completing the first 6 GLB videos, and who are re-randomized to receive the augmented intervention. They will complete the next 6 GLB videos from Week 7-12 and receive digital messages from Week 13-52. They will also work with a trained coach via videoconference (preferred) or phone to receive one-on-one PST from Week 7-24 and group-based PST from Week 25-52. |
Who may qualify
- Ages
- 50 to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Age 50 - 74 years (inclusive)
- Confirmed body mass index (BMI) ≥27.0 based on:
- Diagnosis of 1 or more cardiometabolic condition (prediabetes, metabolic syndrome, type 2 diabetes, hypertension, dyslipidemia) in the EHR
- Willing and able to accept randomization, and provide written informed consent and HIPAA authorization
- Willing and able to participate in all aspects of the data collection and intervention protocols, including remote monitoring with a study-provided wireless weight scale and activity tracker and the use of a study tablet for access of MyChart, REDCap, and Fitbit apps
Key exclusion criteria (13 listed)
- Unable to speak, read, understand English sufficiently for informed consent
- No reliable Wi-Fi Internet access at home
- Self-report of current active weight loss treatment, including research-based commercial weight loss programs (e.g., Weight Watchers, Jenny Craig, HMR, Omada, TOPS), other weight loss or related behavioral health or wellness programs led by trained personnel (professional or lay) at the recruiting clinic or in the local community, and prescription weight loss medications
- Screen positive for active eating disorder (bulimia nervosa or binge eating disorder) using PHQ- eating disorder module
- Planned or prior bariatric surgery within the last 2 years (Note: patients who are more than 2 years post bariatric surgery can participate if otherwise eligible)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Base intervention12 Group Lifestyle Balance videos and digital motivational messages | Behavioural | Group A: Waitlist-Base Intervention, Group C: Base Intervention (Responders), Group D: Base Intervention (Non-responders) |
| Augmented Intervention12 Group Lifestyle Balance videos and digital motivational messages plus remote coaching for one-on-one and group-based problem-solving treatment via videoconference (preferred) or phone | Behavioural | Group B: Waitlist-Augmented Intervention, Group E: Augmented Intervention (Non-responders) |
Primary outcome
Assess change in weight from baseline to 52 weeks
Time frame: Baseline, 52 weeks
All participants will be provided a Fitbit Aria weight scale, a Fitbit Inspire 3 activity tracker, and a study tablet (Samsung Galaxy). At baseline (0) and 52 weeks, a study coordinator at each site who is blinded to randomization will proactively contact participants by phone, email, and/or text to remind them to weigh themselves at the same time on at least 3 days during the week. Participants will be instructed to weigh themselves on their study-provided Aria scale right after waking up and emptying their bladder (and bowel, if possible). They should wear only a t-shirt and undergarments, and bare feet. The investigators will obtain participants' self-monitored weight data using a developed program for automated daily synchronization via the Fitbit open API.
22 secondary outcomes
Assess change in weight from baseline to 12 weeks
Time frame: Baseline, 12 weeks,
Assess trajectories of weight change from baseline to 6, 12, 24, and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks
Assess changes in number of steps using Fitbit activity tracker at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in sleep metrics using Fitbit activity tracker at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in physical activity using the International Physical Activity Questionnaire at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in fruit/veggie/fat/fiber intake at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in efficacy in weight control at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in efficacy in diet change at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in efficacy in physical activity at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in social support/autonomous support per Health Care Climate Questionnaire at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in problem solving ability at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in patient activation at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in perceived stress at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in sleep disturbance score at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in sleep impairment score at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in cognitive functioning at 6, 12, 24 and 52 weeks
Time frame: Baseline, 6 weeks, 12 weeks, 24 weeks, 52 weeks
Assess changes in cardiovascular risk at 52 weeks
Time frame: Baseline, 52 weeks
Assess changes in number/severity of comorbidity at 52 weeks
Time frame: Baseline, 52 weeks
GLB videos viewed
Time frame: Throughout the intervention, up to 1 year
PST coaching sessions completed
Time frame: Throughout the intervention, up to 1 year
Self-monitoring of weight
Time frame: Through study completion, an average of 1 year
Self-monitoring of activity & sleep
Time frame: Through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
Related trials for CARDIOMETABOLIC CONDITIONS
Not yet recruiting
Effects of N-Acyl Taurines on Incretin Levels in Healthy Subjects
Cardiometabolic Conditions
Active, not recruitingObservational study
Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes
Cardiometabolic Risk Factors, Skin Condition
Recruiting
Incretin-based Therapies, Nutrition, and Physical Activity
Obesity & Overweight, Cardiometabolic Conditions
Enrolling by invitation
To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years
Cardiometabolic Conditions, Hypertension (HTN)
Recruiting
Trauma and Cardiometabolic Health in an American Indian Community
Psychological Stress, Cardiometabolic Conditions
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Base intervention and Augmented Intervention in people with CARDIOMETABOLIC CONDITIONS and Obesity, run by University of Illinois at Chicago at 3 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess change in weight from baseline to 52 weeks (time frame: Baseline, 52 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026; AzTrials last refreshed its copy on 31 Oct 2026.